130 related articles for article (PubMed ID: 36460932)
21. MGMT-inhibitor in combination with TGF-βRI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells.
Das A; Henderson FC; Alshareef M; Porto GBF; Kanginakudru I; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
Clin Transl Oncol; 2021 Mar; 23(3):612-619. PubMed ID: 32710211
[TBL] [Abstract][Full Text] [Related]
22. LINC00511 facilitates Temozolomide resistance of glioblastoma cells via sponging miR-126-5p and activating Wnt/β-catenin signaling.
Lu Y; Tian M; Liu J; Wang K
J Biochem Mol Toxicol; 2021 Sep; 35(9):e22848. PubMed ID: 34328678
[TBL] [Abstract][Full Text] [Related]
23. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
[TBL] [Abstract][Full Text] [Related]
24. MAPK8 mediates resistance to temozolomide and apoptosis of glioblastoma cells through MAPK signaling pathway.
Xu P; Zhang G; Hou S; Sha LG
Biomed Pharmacother; 2018 Oct; 106():1419-1427. PubMed ID: 30119215
[TBL] [Abstract][Full Text] [Related]
25. Targeting sphingolipid metabolism with the sphingosine kinase inhibitor SKI-II overcomes hypoxia-induced chemotherapy resistance in glioblastoma cells: effects on cell death, self-renewal, and invasion.
Sousa N; Geiß C; Bindila L; Lieberwirth I; Kim E; Régnier-Vigouroux A
BMC Cancer; 2023 Aug; 23(1):762. PubMed ID: 37587449
[TBL] [Abstract][Full Text] [Related]
26. Down-regulation of MDR1 by Ad-DKK3 via Akt/NFκB pathways augments the anti-tumor effect of temozolomide in glioblastoma cells and a murine xenograft model.
Fujihara T; Mizobuchi Y; Nakajima K; Kageji T; Matsuzaki K; Kitazato KT; Otsuka R; Hara K; Mure H; Okazaki T; Kuwayama K; Nagahiro S; Takagi Y
J Neurooncol; 2018 Sep; 139(2):323-332. PubMed ID: 29779087
[TBL] [Abstract][Full Text] [Related]
27. Piperlongumine-inhibited TRIM14 signaling sensitizes glioblastoma cells to temozolomide treatment.
Kuo YY; Ho KH; Shih CM; Chen PH; Liu AJ; Chen KC
Life Sci; 2022 Nov; 309():121023. PubMed ID: 36202175
[TBL] [Abstract][Full Text] [Related]
28. Guggulsterone from Commiphora mukul potentiates anti-glioblastoma efficacy of temozolomide in vitro and in vivo via down-regulating EGFR/PI3K/Akt signaling and NF-κB activation.
Xu HB; Chen XZ; Yu ZL; Xue F
J Ethnopharmacol; 2023 Jan; 301():115855. PubMed ID: 36280019
[TBL] [Abstract][Full Text] [Related]
29. TROY signals through JAK1-STAT3 to promote glioblastoma cell migration and resistance.
Ding Z; Kloss JM; Tuncali S; Tran NL; Loftus JC
Neoplasia; 2020 Sep; 22(9):352-364. PubMed ID: 32629176
[TBL] [Abstract][Full Text] [Related]
30. The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells.
Kim JE; Lee YJ; Park HR; Lee DG; Jeong KH; Kang H
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32698510
[TBL] [Abstract][Full Text] [Related]
31. Potential drug repurposing of ruxolitinib to inhibit the JAK/STAT pathway for the treatment of patients with epithelial ovarian cancer.
Yunianto I; Currie M; Chitcholtan K; Sykes P
J Obstet Gynaecol Res; 2023 Nov; 49(11):2563-2574. PubMed ID: 37565583
[TBL] [Abstract][Full Text] [Related]
32. Proteins of Wnt signaling pathway in cancer stem cells of human glioblastoma.
Shevchenko V; Arnotskaya N; Zaitsev S; Sharma A; Sharma HS; Bryukhovetskiy A; Pak O; Khotimchenko Y; Bryukhovetskiy I
Int Rev Neurobiol; 2020; 151():185-200. PubMed ID: 32448607
[TBL] [Abstract][Full Text] [Related]
33. Xihuang pill potentiates the anti-tumor effects of temozolomide in glioblastoma xenografts through the Akt/mTOR-dependent pathway.
Fu J; Zhu SH; Xu HB; Xu YQ; Wang X; Wang J; Kong PS
J Ethnopharmacol; 2020 Oct; 261():113071. PubMed ID: 32603676
[TBL] [Abstract][Full Text] [Related]
34. Perivascular signals alter global gene expression profile of glioblastoma and response to temozolomide in a gelatin hydrogel.
Ngo MT; Harley BAC
Biomaterials; 2019 Apr; 198():122-134. PubMed ID: 29941152
[TBL] [Abstract][Full Text] [Related]
35. The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells.
Atif F; Patel NR; Yousuf S; Stein DG
PLoS One; 2015; 10(6):e0131441. PubMed ID: 26110872
[TBL] [Abstract][Full Text] [Related]
36. The interruption of atypical PKC signaling and Temozolomide combination therapy against glioblastoma.
Dey A; Islam SMA; Patel R; Acevedo-Duncan M
Cell Signal; 2021 Jan; 77():109819. PubMed ID: 33147518
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-132 induces temozolomide resistance and promotes the formation of cancer stem cell phenotypes by targeting tumor suppressor candidate 3 in glioblastoma.
Cheng ZX; Yin WB; Wang ZY
Int J Mol Med; 2017 Nov; 40(5):1307-1314. PubMed ID: 28901390
[TBL] [Abstract][Full Text] [Related]
38. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
[TBL] [Abstract][Full Text] [Related]
39. 5-lipoxygenase as a target to sensitize glioblastoma to temozolomide treatment via β-catenin-dependent pathway.
Tang D; Hu Y; Gao W
Neurol Res; 2023 Nov; 45(11):1026-1034. PubMed ID: 37695758
[TBL] [Abstract][Full Text] [Related]
40. The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy.
Skaga E; Skaga IØ; Grieg Z; Sandberg CJ; Langmoen IA; Vik-Mo EO
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1495-1507. PubMed ID: 31028540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
